MG冰球突破官网

Press Release

09
2022.11
Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV
27
2022.10
Acceptance Of The Application For Clinical Trial Of Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
19
2022.08
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
10
2022.08
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

Publication News

2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques
MG冰球突破官网_冰球突破正规网站-2026FIFA世界杯
www.skyzeyes.net
冰球突破正规网站
冰球突破正规网站
MG冰球突破官网
MG冰球突破官网_冰球突破正规网站-2026FIFA世界杯
www.skyzeyes.net
MG冰球突破官网_冰球突破正规网站-2026FIFA世界杯
MG冰球突破官网
MG冰球突破官网_冰球突破正规网站-2026FIFA世界杯
MG冰球突破官网
冰球突破正规网站
金沙体育推荐老品牌网站